A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

NCT02575482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Disorders

Interventions

DRUG: SUVN-D4010
DRUG: Placebo

Sponsor

Suven Life Sciences Limited